Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines

Posted by |2020-01-01T02:30:16-07:00December 24th, 2019|

The FDA on Monday approved a pill from Allergan to treat migraine in adults. The treatment, ubrogepant (Ubrelvy), is part of a new class of migraine medicines designed to block calcitonin gene-related peptide (CGRP), a protein thought to play a role in pain transmission. Ubrogepant is the first CGRP drug in tablet form to get […]

Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal

Posted by |2019-12-23T12:06:48-07:00December 23rd, 2019|

Swiss biopharma Roche is betting more than $1 billion that Sarepta Therapeutics, which recently won FDA approval for its second RNA medicine for Duchenne muscular dystrophy, will get its lead gene therapy treatment across the finish line too. The deal, one of the biggest ever US biopharma licensing agreements, gives Roche the right outside of […]

Encoded Makes Chief Regulatory, People & Culture Officer Appointments

Posted by |2019-12-23T02:30:06-07:00December 20th, 2019|

Encoded Therapeutics added two people to its C-suite this week. The South San Francisco-based company named Nancy Boman as its chief regulatory officer and Monique Bobadilla as its chief people and culture officer. Encoded, which raised $104 million in June, aims to develop gene therapies to treat diseases the technique currently can’t address. Its lead […]

Biogen Strikes Alzheimer’s Deal, Paying $45M for Ionis Tau Drug Rights

Posted by |2019-12-19T15:36:01-07:00December 19th, 2019|

When it comes to Alzheimer’s disease, Biogen isn’t putting all of its eggs in the same basket. In the latest development of a multi-drug and multi-disease collaboration, the company has licensed an experimental Ionis Pharmaceuticals compound that works in a different way than the therapies currently in its pipeline for neurodegenerative diseases. On Thursday, Ionis […]

ArcherDX Raises $55M to Help Physicians Pick Best Cancer Therapies

Posted by |2019-12-18T16:12:27-07:00December 18th, 2019|

2020 will be a big year for ArcherDX, says its CEO on the heels of raising $55 million to advance its companion diagnostics platform—which is intended to make precision medicine an option for patients in earlier stages of disease. Headquartered in Boulder, CO, the company will use the Series C funds to expand its global […]

Nimbus Therapeutics Taps Annie Chen to Lead Subsidiary

Posted by |2019-12-17T14:44:26-07:00December 17th, 2019|

Nimbus Therapeutics has named Annie Chen to the role of president at its subsidiary, Nimbus Lakshmi. Chen is currently chief medical officer of Cambridge, MA-based Nimbus Therapeutics, and she will continue serving in that role. The company uses software to discover and design new drugs, some of which are developed by its subsidiaries. Nimbus Lakshmi […]

Organovo’s Demise Offers Path for Tarveda to Join the Public Markets

Posted by |2019-12-16T20:29:51-07:00December 16th, 2019|

Organovo raised millions of dollars from investors to fuel its goal of developing 3D “bioprinted” human tissues for use in people with end-stage liver disease and other life-threatening illnesses. But the San Diego company fell short of bringing its lead regenerative medicine program into clinical trials, and now it is charting a course as a […]

Amarin’s Fish-Oil Pill Wins FDA Nod to Cut Heart Attack, Stroke Risk

Posted by |2019-12-16T02:30:07-07:00December 13th, 2019|

A prescription pill derived from fish-oil pill received the regulatory nod Friday to expand its use as a supplementary treatment, alongside statins, to more patients at risk of heart attack or stroke. The FDA approved the Amarin Pharma drug, icosapent ethyl (Vascepa), for use as a secondary treatment for adults who are taking statins and have […]

miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal

Posted by |2019-12-12T10:51:03-07:00December 12th, 2019|

MicroRNA therapies developer miRagen Therapeutics is scaling back work on its most advanced cancer drug candidate and shifting resources to a compound being developed to treat fibrosis in the lungs. The pipeline shuffle will be accompanied by a corporate shakeup. Boulder, CO-based miRagen (NASDAQ: MGEN) is also laying off some of its staff. The company […]

Prometheus Bio Taps Thierry Dervieux as Chief Development Officer

Posted by |2019-12-11T12:41:54-07:00December 11th, 2019|

Prometheus Biosciences on Tuesday said it has appointed Thierry Dervieux as chief development officer, diagnostics, and medical laboratory director. The San Diego-based biotech, created this summer through the acquisition of Prometheus Laboratories by Precision IBD, is working to create new drugs and companion diagnostics for people with gastroenterology disorders and autoimmune diseases. Dervieux was most […]

Flexion Co-Founder, Chief Scientific Officer Neil Bodick to Retire

Posted by |2019-12-10T14:09:18-07:00December 10th, 2019|

Neil Bodick, chief scientific officer of Flexion Therapeutics (NASDAQ: FLXN), will retire on Jan. 3. After co-founding the company in 2007, Bodick served as its chief medical officer. He became chief scientific officer in 2017 following FDA approval of the company’s extended-release formulation of triamcinolone acetonide (Zilretta), a treatment for knee pain. After retiring, Flexion […]

Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx

Posted by |2019-12-09T17:01:19-07:00December 9th, 2019|

Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions. Now French biopharma Sanofi has struck a deal to add the startup to its oncology business in a transaction that values the company at about $2.5 billion. The move is […]
Load More Posts